Modality
ADC
MOA
FXIai
Target
PARP
Pathway
Checkpoint
PNHCholangiocarcinoma
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
Aug 2021
→ May 2030
Phase 3Current
NCT06998878
1,138 pts·Cholangiocarcinoma
2021-09→2029-09·Terminated
NCT08524402
1,247 pts·Cholangiocarcinoma
2021-08→TBD·Completed
NCT05659076
260 pts·Cholangiocarcinoma
2025-02→2026-08·Recruiting
+1 more trial
5,440 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-08-034mo awayPh3 Readout· Cholangiocarcinoma
2029-09-283.5y awayPh3 Readout· Cholangiocarcinoma
2030-05-234.1y awayPh3 Readout· Cholangiocarcinoma
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Complet…
P3
Termina…
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2026-08-03 · 4mo away
Cholangiocarcinoma
Ph3 Readout
2029-09-28 · 3.5y away
Cholangiocarcinoma
Ph3 Readout
2030-05-23 · 4.1y away
Cholangiocarcinoma
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06998878 | Phase 3 | Cholangiocarcinoma | Terminated | 1138 | PANSS |
| NCT08524402 | Phase 3 | Cholangiocarcinoma | Completed | 1247 | EFS |
| NCT05659076 | Phase 3 | Cholangiocarcinoma | Recruiting | 260 | Biomarker |
| NCT06493838 | Phase 3 | Cholangiocarcinoma | Not yet recr... | 2795 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP |